The UCCC proposes three research Staff Investigators with particular focus in three strategic areas of UCCC development?metastasis and tumor-host microenvironment, cancer stem cell and regenerative medicine, and cancer survivorship. Each Staff Investigator will be responsible for overseeing the coordination, integration and development of research activities in their respective areas across the six Research Programs. Virginia Borges, MD, will serve in the role of Staff Investigator for metastasis and tumor-host microenvironment. She will be responsible for promoting the theme of tumor-host microenvironment interactions and how these affect tumor progression with a specific focus on metastasis across the programs, with the goal of building scientific collaborations to facilitate the development of a new Metastasis and Tumor Microenvironment (MTM) Program. Her research provides a paradigm and model of how immunologic and inflammatory cells promote metastasis, and as a practicing oncologist, she has the knowledge, experience and track record to take these findings to the clinic. Stephen Hunger, MD, will serve in the role of Staff Investigator for cancer stem cell and regenerative medicine. He will be responsible for promoting hematologic oncology research themes including transplantation and stem cell therapy across the programs, with an emphasis on building scientific collaborations to facilitate the development of a new Cancer Stem Cell Program. Dr. Hunger Is an internationally recognized leader in translational research and clinical trials related to childhood acute lymphoblastic leukemia (ALL), with over 100 peer-reviewed publications. Jean Kutner, MD will serve in the role of Staff Investigator for cancer survivorship and palliative care. She will be responsible for promoting survivorship and palliative care research themes across the programs, with an emphasis on building scientific collaborations to facilitate the development of a new Cancer Survivorship Program in the upcoming funding period. Her research in cancer survivorship issues, including late effects and palliative care, provides the appropriate background to oversee the efforts to develop a new survivorship program within the UCCC.
Research Staff Investigators (SI) are important contributors to the programmatic and translational activities of the Cancer Center. The UCCC has 3 Si's in cancer immunology, pediatric oncology/stem cells and cancer survivorship to promote those research themes across the scientific programs and advance the development of new programs in the areas of Cancer Stem Cells, Metastasis and Tumor Microenvironment, and Cancer Survivorship.
|Saichaemchan, S; Ariyawutyakorn, W; Varella-Garcia, M (2016) Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy. Curr Mol Med 16:40-62|
|Gillen, Austin E; Yamamoto, Tomomi M; Kline, Enos et al. (2016) Improvements to the HITS-CLIP protocol eliminate widespread mispriming artifacts. BMC Genomics 17:338|
|Justice, Cristina M; Bishop, Kevin; Carrington, Blake et al. (2016) Evaluation of IRX Genes and Conserved Noncoding Elements in a Region on 5p13.3 Linked to Families with Familial Idiopathic Scoliosis and Kyphosis. G3 (Bethesda) 6:1707-12|
|Eckwahl, Matthew J; Arnion, Helene; Kharytonchyk, Siarhei et al. (2016) Analysis of the human immunodeficiency virus-1 RNA packageome. RNA 22:1228-38|
|Iguchi, Nao; Malykhina, Anna P; Wilcox, Duncan T (2016) Inhibition of HIF Reduces Bladder Hypertrophy and Improves Bladder Function in Murine Model of Partial Bladder Outlet Obstruction. J Urol 195:1250-6|
|Seedorf, Gregory; Metoxen, Alexander J; Rock, Robert et al. (2016) Hepatocyte growth factor as a downstream mediator of vascular endothelial growth factor-dependent preservation of growth in the developing lung. Am J Physiol Lung Cell Mol Physiol 310:L1098-110|
|Agarwal, Neeraj; Dancik, Garrett M; Goodspeed, Andrew et al. (2016) GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis. Cancer Res 76:5175-85|
|Helfrich, Barbara A; Kim, Jihye; Gao, Dexiang et al. (2016) Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther 15:2314-2322|
|Munson, Daniel J; Egelston, Colt A; Chiotti, Kami E et al. (2016) Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. Proc Natl Acad Sci U S A 113:8272-7|
|Scott, Aaron J; Lieu, Christopher H; Messersmith, Wells A (2016) Therapeutic Approaches to RAS Mutation. Cancer J 22:165-74|
Showing the most recent 10 out of 1302 publications